Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
4,427
Views
7
CrossRef citations to date
0
Altmetric
Review

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents

Chao Wanga The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaCorrespondence[email protected]
View further author information
,
Yujing Zhangc The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, ChinaCorrespondence[email protected]
View further author information
,
Lingyu Shia The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaView further author information
,
Shanbo Yanga The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaView further author information
,
Jing Changa The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaView further author information
,
Yingjie Zhonga The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaView further author information
,
Qian Lia The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, ChinaCorrespondence[email protected]
View further author information
&
Dongming Xinga The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China;b Cancer Institute, Qingdao University, Qingdao, China;d School of Life Sciences, Tsinghua University, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1437-1453 | Received 12 Dec 2021, Accepted 02 May 2022, Published online: 19 May 2022

References

  • Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1437–9.
  • Gu S, Cui D, Chen X, et al. PROTACs: an emerging targeting technique for protein degradation in drug discovery. Bioessays 2018;40:e1700247.
  • Yang J, Li Y, Aguilar A, et al. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders. J Med Chem 2019;62:9471–87.
  • Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew Chem Int Ed Engl 2016;55:1966–73.
  • Kathleen MS, Kyung BK, Akiko K, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. P Nant Acad SCI USA 2001;98:8554–9.
  • Liang D, Yu Y, Ma Z. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. Eur J Med Chem 2020;200:112426.
  • Drummond ML, Williams CI. In silico modeling of PROTAC-mediated ternary complexes: validation and application. J Chem Inf Model 2019;59:1634–44.
  • An S, Fu L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 2018;36:553–62.
  • Wang C, Zhang Y, Wang J, et al. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. Eur J Med Chem 2022;227:113906.
  • Wang C, Zhang Y, Wu Y, et al. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur J Med Chem 2021;225:113749.
  • Farnaby W, Koegl M, Roy MJ, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol 2019;15:672–80.
  • Martin-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem 2021;210:112993.
  • Zeng S, Huang W, Zheng X, et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur J Med Chem 2021;210:112981.
  • Sakamoto KM, Kim KB, Kumagai A, et al. PROTACS: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A 2001;98:8554–9.
  • Schneekloth JS Jr, Fonseca FN, Koldobskiy M, et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J Am Chem Soc 2004;126:3748–54.
  • Schneekloth AR, Pucheault M, Tae HS, et al. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg Med Chem Lett 2008;18:5904–8.
  • Hughes SJ, Testa A, Thompson N, et al. The rise and rise of protein degradation: opportunities and challenges ahead. Drug Discov Today 2021;21:1359–6446.
  • Itoh Y, Ishikawa M, Naito M, et al. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J Am Chem Soc 2010;132:5820–6.
  • Okuhira K, Ohoka N, Sai K, et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett 2011;585:1147–52.
  • Okuhira K, Demizu Y, Hattori T, et al. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 2013;104:1492–8.
  • Buckley DL, Van Molle I, Gareiss PC, et al. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc 2012;134:4465–8.
  • Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401–10.
  • Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999;13:239–52.
  • Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. J Virol 1994;68:2521–8.
  • Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168–74.
  • Ndubaku C, Cohen F, Varfolomeev E, et al. Targeting inhibitor of apoptosis proteins for therapeutic intervention. Future Med Chem 2009;1:1509–25.
  • Yang L, Cao Z, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Canc Res 2003;63:6815–24.
  • Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Canc Res 2000;6:1796–803.
  • Ma Z, Ji Y, Yu Y, et al. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy. Eur J Med Chem 2021;216:113247.
  • Naito M, Ohoka N, Shibata N. SNIPERs-Hijacking IAP activity to induce protein degradation. Drug Discov Today Technol 2019;31:35–42.
  • Ishikawa M, Tomoshige S, Demizu Y, et al. Selective degradation of target proteins by chimeric small-molecular drugs, PROTACs and SNIPERs. Pharmaceuticals (Basel) 2020;13:74.
  • Naito M, Ohoka N, Shibata N, et al. Targeted protein degradation by chimeric small molecules, PROTACs and SNIPERs. Front Chem 2019;7:849.
  • Scott DE, Bayly AR, Abell C, et al. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov 2016;15:533–50.
  • Cong H, Xu L, Wu Y, et al. Inhibitor of apoptosis protein (IAP) antagonists in anticancer agent discovery: current status and perspectives. J Med Chem 2019;62:5750–72.
  • Li L, Thomas RM, Suzuki H, et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004;305:1471–4.
  • Sekine K, Takubo K, Kikuchi R, et al. Small molecules destabilize cIAP1 by activating auto-ubiquitylation. J Biol Chem 2008;283:8961–8.
  • Weng G, Shen C, Cao D, et al. PROTAC-DB: an online database of PROTACs. Nucleic Acids Res 2021;49:1381–7.
  • Bricelj A, Steinebach C, Kuchta R, et al. E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points. Front Chem 2021;9:707317.
  • Campos C, Sotomayor P, Jerez D, et al. Exercise and prostate cancer: from basic science to clinical applications. Prostate 2018;78:639–45.
  • Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.
  • Shibata N, Nagai K, Morita Y, et al. Development of protein degradation inducers of androgen receptor by conjugation of androgen receptor ligands and inhibitor of apoptosis protein ligands. J Med Chem 2018;61:543–75.
  • Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49–63.
  • Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421–8.
  • Zhang X, He Y, Zhang P, et al. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem 2020;199:112397.
  • Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172–83.
  • Lai AC, Toure M, Hellerschmied D, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl 2016;55:807–10.
  • Demizu Y, Shibata N, Hattori T, et al. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg Med Chem Lett 2016;26:4865–9.
  • Shibata N, Miyamoto N, Nagai K, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci 2017;108:1657–66.
  • Shimokawa K, Shibata N, Sameshima T, et al. Targeting the allosteric site of oncoprotein bcr-abl as an alternative strategy for effective target protein degradation. ACS Med Chem Lett 2017;8:1042–7.
  • Zengerle M, Chan KH, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem Biol 2015;10:1770–7.
  • Kounde CS, Shchepinova MM, Saunders CN, et al. A caged E3 ligase ligand for PROTAC-mediated protein degradation with light. Chem Commun (Camb) 2020;56:5532–5.
  • Ohoka N, Ujikawa O, Shimokawa K, et al. Different degradation mechanisms of inhibitor of apoptosis proteins (IAPs) by the specific and nongenetic IAP-dependent protein eraser (SNIPER). Chem Pharm Bull (Tokyo) 2019;67:203–9.
  • Pan ZY, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58–61.
  • Sun Y, Zhao X, Ding N, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 2018;28:779–81.
  • Sun Y, Ding N, Song Y, et al. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 2019;33:2105–10.
  • Zorba A, Nguyen C, Xu Y, et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A 2018;115:7285–92.
  • Schiemer J, Horst R, Meng Y, et al. Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes. Nat Chem Biol 2021;17: 152–60.
  • Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 2016;6:353–67.
  • Walker AJ, Wedam S, Amiri-Kordestani L, et al. FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2016;22:4968–72.
  • Steinebach C, Ng YLD, Sosic I, et al. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci 2020;11:3474–86.
  • Dominici MD, Porazzi P, Xiao Y, et al. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and-independent effects by CDK6-specific PROTACs. Blood 2020;135:1560–73.
  • Su S, Yang Z, Gao H, et al. Potent and preferential degradation of cdk6 via proteolysis targeting chimera degraders. J Med Chem 2019;62:7575–82.
  • Anderson NA, Cryan J, Ahmed A, et al. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs. Bioorg Med Chem Lett 2020;30:127106.
  • Itoh Y, Ishikawa M, Kitaguchi R, et al. Development of target protein-selective degradation inducer for protein knockdown. Bioorg Med Chem 2011;19:3229–41.
  • Itoh Y, Ishikawa M, Kitaguchi R, et al. Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist. Bioorg Med Chem Lett 2012;22:4453–577.
  • Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169–81.
  • Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341–54.
  • Burslem GM, Smith BE, Lai AC, et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem Biol 2018;25:67–77.
  • Zhang X, Xu F, Tong L, et al. Design and synthesis of selective degraders of EGFRL858R/T790M mutant. Eur J Med Chem 2020;192:112199.
  • Georgiadis D, Mpakali A, Koumantou D, et al. Inhibitors of ER aminopeptidase 1 and 2: from design to clinical application. Curr Med Chem 2019;26:2715–29.
  • Demizu Y, Misawa T, Nagakubo T, et al. Structural development of stabilized helical peptides as inhibitors of estrogen receptor (ER)-mediated transcription. Bioorg Med Chem 2015;23:4132–8.
  • Itoh Y, Kitaguchi R, Ishikawa M, et al. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers. Bioorg Med Chem 2011;19:6768–78.
  • Demizu Y, Okuhira K, Motoi H, et al. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. Bioorg Med Chem Lett 2012;22:1793–6.
  • Demizu Y, Ohoka N, Nagakubo T, et al. Development of a peptide-based inducer of nuclear receptors degradation. Bioorg Med Chem Lett 2016;26:2655–8.
  • Ohoka N, Okuhira K, Ito M, et al. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs). J Biol Chem 2017;292:4556–70.
  • Ohoka N, Morita Y, Nagai K, et al. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation. J Biol Chem 2018;293:6776–90.
  • Disch JS, Duffy JM, Lee ECY, et al. Bispecific estrogen receptor α degraders incorporating novel binders identified using DNA-encoded chemical library screening. J Med Chem 2021;64:5049–66.
  • Yokoo H, Ohoka N, Takyo M, et al. Peptide stapling improves the sustainability of a peptide-based chimeric molecule that induces targeted protein degradation. Int J Mol Sci 2021;22:8772.
  • Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541–52.
  • Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13:673–91.
  • Cao J, Zhao W, Liu Q, et al. Development of a Bestatin-SAHA hybrid with dual inhibitory activity against APN and HDAC. Molecules 2020;25:4991.
  • O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015;66:311–28.
  • Field SD, Arkin J, Li J, et al. Selective downregulation of JAK2 and JAK3 by an ATP-competitive pan-JAK inhibitor. ACS Chem Biol 2017;12:1183–7.
  • Shah RR, Redmond JM, Mihut A, et al. Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs. Bioorg Med Chem 2020;28:115326.
  • Ohoka N, Misawa T, Kurihara M, et al. Development of a peptide-based inducer of protein degradation targeting NOTCH1. Bioorg Med Chem Lett 2017;27:4985–8.
  • Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009;462:182–8.
  • Huryn DM, Kornfilt DJP, Wipf P. p97: an emerging target for cancer, neurodegenerative diseases, and viral infections. J Med Chem 2020;63:1892–907.
  • Barthelme D, Sauer RT. Origin and functional evolution of the Cdc48/p97/VCP AAA + protein unfolding and remodeling machine. J Mol Biol 2016;428:1861–9.
  • Donovan KA, Ferguson FM, Bushman JW, et al. Mapping the degradable kinome provides a resource for expedited degrader development. Cell 2020;183:1714–31.
  • Gergely F, Karlsson C, Still I, et al. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci U S A 2000;97:14352–7.
  • LeRoy PJ, Hunter JJ, Hoar KM, et al. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res 2007;67:5362–70.
  • Ohoka N, Nagai K, Hattori T, et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell Death Dis 2014;5:e1513.
  • Rittchen S, Heinemann A. Therapeutic potential of hematopoietic prostaglandin D2 synthase in allergic inflammation. Cells 2019;8:619.
  • Aritake K, Kado Y, Inoue T, et al. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem 2006;281:15277–86.
  • Yokoo H, Shibata N, Naganuma M, et al. Development of a hematopoietic prostaglandin D synthase-degradation inducer. ACS Med Chem Lett 2021;12:236–41.
  • Chaudhary D, Robinson S, Romero DL. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem 2015;58:96–110.
  • Zhang J, Fu L, Shen B, et al. Assessing IRAK4 functions in ABC DLBCL by IRAK4 kinase inhibition and protein degradation. Cell Chem Biol 2020;27:1500–9.
  • Nunes J, McGonagle GA, Eden J, et al. Targeting IRAK4 for degradation with PROTACs. ACS Med Chem Lett 2019;10:1081–5.
  • Jensen S, Seidelin JB, LaCasse EC, et al. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Sci Signal 2020;13:8295.
  • Hyun S, Shin D. Chemical-mediated targeted protein degradation in neurodegenerative diseases. Life(Basel) 2021;11:607.
  • Mares A, Miah AH, Smith IED, et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun Biol 2020;3:140.
  • Miah AH, Smith IED, Rackham M, et al. Optimization of a series of RIPK2 PROTACs. J Med Chem 2021;64:12978–3003.
  • Reiner A, Dragatsis I, Dietrich P. Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol 2011;98:325–72.
  • Tomoshige S, Nomura S, Ohgane K, et al. Discovery of small molecules that induce the degradation of Huntingtin. Angew Chem Int Ed Engl 2017;56:11530–3.
  • Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014;26:2016–29.
  • Bhat A, Ray B, Mahalakshmi AM, et al. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacol Res 2020;160:105078.
  • Tsukumo Y, Tsuji G, Yokoo H, et al. Protocols for synthesis of SNIPERs and the methods to evaluate the anticancer effects. Methods Mol Biol 2021;2365:331–47.
  • Wang KLiF, Cao WB, Lv XX, et al. TRIB3 promotes APL progression through stabilization of the oncoprotein PML-RARα and inhibition of p53-mediated senescence. Cancer Cell 2017;31:697–710.
  • Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014;27:3–9.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.